Fuji invests in TeraRecon

TeraRecon Inc. has received a strategic capital investment from Fuji Film Co. of Tokyo, Japan.

The agreement, which occurred in March, relates to collaboration on new product and technology development. Fuji acquired 300,000 shares of newly issued series G preferred stock, representing 1.9 percent of issued equity in TeraRecon, for $4.95 million.

Under the terms of the agreement, TeraRecon will apply its signal and image processing processor and software technologies to new product and technology development with Fuji.

Fuji says it made the decision to invest after evaluation of this technology for 3D image processing and the high-speed processing of large image collections produced by modern medical imaging examinations.

TeraRecon has deployed the same technologies in its own line of end-user products including 3D and 4D image processing workstations and servers, and high-pixel density, high-resolution flat panel display systems.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup